The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Bupivacaine Extended-Release Liposome Injection for Prolonged Postsurgical Analgesia in Patients Undergoing Hemorrhoidectomy: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Abstract
BACKGROUND: Bupivacaine extended-release liposome injection is a novel formulation of bupivacaine designed to achieve long-acting postoperative analgesia. OBJECTIVE: The aim of this study was to compare the magnitude and duration of postoperative analgesia from a single dose of bupivacaine extended-release injection with placebo administered intraoperatively in patients undergoing hemorrhoidectomy. DESIGN: This evaluation was a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 study. SETTINGS: Data were obtained from 13 centers in the Republic of Georgia, Poland, and Serbia. PATIENTS: Included in this study were patients aged 18 to 86 years undergoing excisional hemorrhoidectomy. INTERVENTIONS: All patients received either a single dose of bupivacaine extended-release 300 mg or placebo administered intraoperatively via wound infiltration. MAIN OUTCOME MEASURE: The cumulative pain score was assessed by measurement of the area under the curve of pain intensity through 72 hours after study drug administration. RESULTS: One hundred eighty-nine patients were randomly assigned and treated; 186 completed the study. Pain intensity scores were significantly lower in the bupivacaine extended-release group in comparison with the group receiving placebo (141.8 vs 202.5, P < .0001). More patients in the bupivacaine extended-release group remained opioid free from 12 hours (59%) to 72 hours (28%) after surgery compared with patients receiving placebo (14% and 10%; P < .0008 through 72 h). The mean total amount of opioids consumed through 72 hours was 22.3 mg and 29.1 mg in the bupivacaine extended-release and placebo groups (P ≤ .0006). The median time to first opioid use was 14.3 hours in the bupivacaine extended-release group vs 1.2 hours in the placebo group (P < .0001). A greater proportion of patients in the bupivacaine extended-release group were satisfied with their postsurgical analgesia (95% vs 73%, P = .0007) than in the placebo group. CONCLUSIONS: Bupivacaine extended-release demonstrated a statistically significant reduction in pain through 72 hours, decreased opioid requirements, delayed time to first opioid use, and improved patient satisfaction compared with placebo after hemorrhoidectomy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
Apfelbaum, J. L., Chen, C., Mehta, S. S., & Gan, A. T. J. (2003) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000068822.10113.9e · Cited by 2,203
Chronic Pain as an Outcome of Surgery: A Review of Predictive Factors
Perkins, F. M., & Kehlet, H. (2000) · Anesthesiology · doi:10.1097/00000542-200010000-00038 · Cited by 1,341
Ambulatory surgery in the United States: development and prospects
Burns, L. A., & Ferber, M. S. (1981) · Journal of Ambulatory Care Management · doi:10.1097/00004479-198108000-00003 · Cited by 852
Møiniche, S., Kehlet, H., & Dahl, J. B. (2002) · Anesthesiology · doi:10.1097/00000542-200203000-00032 · Cited by 815
Macrae, W. A. (2001) · British Journal of Anaesthesia · doi:10.1093/bja/87.1.88 · Cited by 672
National Hospital Discharge Survey: 2007 summary.
Hall, M. J., DeFrances, C. J., Williams, S. N., Golosinskiy, A., & Schwartzman, A. (2010) · PubMed · Cited by 626
Incidence, Prevalence, and Management of Opioid Bowel Dysfunction
Pappagallo, M. (2001) · The American Journal of Surgery · doi:10.1016/s0002-9610(01)00782-6 · Cited by 531
Acute Pain Management: Programs in U.S. Hospitals and Experiences and Attitudes among U.S. Adults
Warfield, C. A., & Kahn, C. H. (1995) · Anesthesiology · doi:10.1097/00000542-199511000-00023 · Cited by 412
Cited by
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Davis, B. R., Lee-Kong, S. A., Migaly, J., Feingold, D. L., & Steele, S. R. (2018) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001030 · Cited by 344
Liposomal bupivacaine: a review of a new bupivacaine formulation
Cummings, III, & Chahar (2012) · Journal of Pain Research · doi:10.2147/jpr.s27894 · Cited by 272
The use of lipid-based nanocarriers for targeted pain therapies
Hua, S., & Wu, S. Y. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00143 · Cited by 268
Devin, C. J., & McGirt, M. J. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.01.003 · Cited by 260
Metadata
- Authors
- Gorfine, S. R., Onel, E., Patou, G., & Krivokapic, Z. V.
- Venue
- Diseases of the Colon & Rectum
- Published
- 2011-12
- Volume
- 54
- Issue
- 12
- Pages
- 1552-1559
- ISSN
- 0012-3706 (ISSN-L)
- OpenAlex
- W1988728097
- Cited by
- 352
- References
- 22
- FWCI
- 14.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bupivacaine Extended-Release Liposome Injection for Prolonged Postsurgical Analgesia in Patients Undergoing Hemorrhoidectomy: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. https://app.cochat.ai/papers/10.1097/dcr.0b013e318232d4c1
- The paper
- Gorfine, S. R., Onel, E., Patou, G., & Krivokapic, Z. V. (2011). Bupivacaine Extended-Release Liposome Injection for Prolonged Postsurgical Analgesia in Patients Undergoing Hemorrhoidectomy: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Diseases of the Colon & Rectum. https://doi.org/10.1097/dcr.0b013e318232d4c1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.